





Disorders of Gut-Brain Interactions (Functional GI disorders)






























Indication	Medication	Mechanism of action	Recommendation AGA/ACG	Quality of evidence AGA/ACG	Abdominal Pain Relief	Specific considerations
IBS-D	Alosetron	5-HT4 receptor secretagogue	Conditional/Weak	Moderate/Low	Yes	Risk of sever constipation and IC (FDA risk mitigation strategy).
	Eluxadoline	Mixed opioid receptor antagonist	Strong/Weak	Moderate	Yes	Contraindicated: SOD, CCY, EtOH, pancreatitis, severe liver impairment
	Rifaximin	Non-adsorbable Abx	Conditional/Weak	Moderate	Yes	
IBS-C	Linaclotide	GC-C receptor agonist	Strong	High	Yes	
	Plecanatide	GC-C receptor agonist	Strong	Moderate	Yes	
	Lubiprostone	Type 2 CL channel agonist	Conditional/Strong	Moderate	Yes	
	Tenapanor	NHE3→Ph			Yes	Not available yet in the US
	Tegaserod	5-HT4 receptor secretagogue			Yes	Women <65 with no CVS risk factors
	PEG-3350		Conditional	Low	No	
IBS-All	Antispasmodic		Conditional/Weak	Low	Yes	
	Peppermint Oil		Conditional/Weak	Low	Yes	
	TCA		Conditional/Strong	Low/High	Yes	
FD	PPI		Strong	Moderate	Yes	
	Prokinetics		Conditional	Very Low	Yes	

	Starting dose	Dose titration	Common side effects		
ricyclic antidepressants ^a (eg, amitriptyline or nortriptyline)	10 mg at night	By 10 mg/wk or 10 mg/fortnight according to response to treatment and tolerability to a maximum of 30–50 mg at night	Sedation, dry eyes, dry mouth, constipation		
Serotonin- norepinephrine reuptake inhibitors (eg, duloxetine)	30 mg once daily	According to response to treatment and tolerability to a maximum of 60 mg once daily	Sedation, dry mouth, constipati or diarrhea, anxiety, reduced appetite, nausea, headache, fatigue		
<i>lirtazapine</i>	15 mg once daily	According to response to treatment and tolerability to a maximum of 45 mg once daily	Sleep disorders, constipation or diarrhea, anxiety, increased appetite and weight gain, nausea, headache, fatigue		
Secondary amines include desiprami	ine and nortriptyline; tertiary amine	s include amitriptyline and imipramine. Second			



Treatment	IBS	Functional Dyspepsia	Other FGID
Tricyclics (TCAs)	+	+	Non-cardiac chest pain Functional heartburn
SSRI	±	No effect	NCCP Functional heartburn
SNRI	+?	No effect (venlafaxine) ? Other SNRI	NCCP
Delta ligand agents	+	+	
Azapirone	+	+	
Atypical antipsychotics	+	+	
Ford et al. Am J Gastroenterol 2018;11 Chang, Sultan, Lembo. Gastroenterolo Drossman DA et al. Gastroenterology	gy 2014;147:1149-1172		Pharmacol Ther. 2019;49:389–397 Dptions Neurol (2019) 21: 18





20th Annual Pain Management Conference Practical Pair Management for Health Care Practitioners	Creighton UNIVERSITY	Creighton University Health Sciences Continuing Education Consortium School of Medicine	College of Nursing School of Pharmacy and Health Professions School of Dentistry	CHI Health	